(vianews) - lumibird (lbird.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| lumibird (lbird.pa) | €12.22 | 1.25% | 5.68% |
| tubize-fin (tub.br) | €74.40 | 1.16% | 4.93% |
| ipsen (ipn.pa) | €107.40 | 1.08% | 12.52% |
| vetoquinol (veto.pa) | €98.40 | 1.02% | 12.13% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. lumibird (lbird.pa)
1.25% forward dividend yield and 5.68% return on equity
lumibird sa designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. it operates in two segments, photonics and medical. the company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, laser rangefinder and lidar wind doppler lidar, medical and ophthalmological equipment. its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. the company was incorporated in 1970 and is headquartered in lannion, france.
earnings per share
as for profitability, lumibird has a trailing twelve months eps of €0.44.
pe ratio
lumibird has a trailing twelve months price to earnings ratio of 27.77. meaning, the purchaser of the share is investing €27.77 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.68%.
more news about lumibird.
2. tubize-fin (tub.br)
1.16% forward dividend yield and 4.93% return on equity
financière de tubize sa operates as a mono holding company whose sole investment is a stake in ucb which is a biopharma company in belgium. the company is based in brussels, belgium.
earnings per share
as for profitability, tubize-fin has a trailing twelve months eps of €2.
pe ratio
tubize-fin has a trailing twelve months price to earnings ratio of 37.2. meaning, the purchaser of the share is investing €37.2 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.93%.
more news about tubize-fin.
3. ipsen (ipn.pa)
1.08% forward dividend yield and 12.52% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. it offers somatuline for neuroendocrine tumors and acromegaly; dysport for motor muscular disorders and medical aesthetics; decapeptyl for the treatment of advanced metastatic prostate cancer; cabometyx for renal cell and second-line hepatocellular carcinoma; onivyde for second-line metastatic pancreatic cancer; and tazverik to treat third-line follicular lymphoma. the company also provides nutropinaq for growth failure in children due to growth hormone (gh) deficiency, turner syndrome or chronic renal insufficiency, and gh deficiency in adults; and increlex for growth failure in children and adolescents. in addition, it offers xermelo for the treatment of carcinoid syndrome; and cometriq to treat medullary thyroid cancer. ipsen s.a. has agreements with debiopharm; exelixis; galderma; blueprint medicines; tersera therapeutics; rhythm pharmaceuticals; teijin; schwabe; bakx therapeutics inc.; and exicure. the company was founded in 1929 and is headquartered in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €4.98.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 21.57. meaning, the purchaser of the share is investing €21.57 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.52%.
revenue growth
year-on-year quarterly revenue growth grew by 8.4%, now sitting on 3.28b for the twelve trailing months.
yearly top and bottom value
ipsen's stock is valued at €107.40 at 01:30 est, way below its 52-week high of €130.70 and way higher than its 52-week low of €94.85.
more news about ipsen.
4. vetoquinol (veto.pa)
1.02% forward dividend yield and 12.13% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 19.8. meaning, the purchaser of the share is investing €19.8 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.
yearly top and bottom value
vetoquinol's stock is valued at €98.40 at 01:30 est, below its 52-week high of €98.60 and way above its 52-week low of €76.30.
moving average
vetoquinol's value is way above its 50-day moving average of €83.09 and way higher than its 200-day moving average of €86.42.more news about vetoquinol.